Brinavess 500 mg, Konzentrat zur Herstellung einer Infusionslösung

7680613040032 CH-61304 Konzentrat
Brinavess 500 mg, Konzentrat zur Herstellung einer Infusionslösung
Brinavess 500 mg, Konzentrat zur Herstellung einer Infusionslösung
Brinavess 500 mg, Konzentrat zur Herstellung einer Infusionslösung
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
01/02/2022
Summary of Product Characteristics
Français
01/02/2022
Summary of Product Characteristics
Italien
01/02/2022

Detailed composition

Substance Quantity Type Category
(N/A)
500.0 MG Substance WIZUS
(N/A)
452.5 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
78.75 MG Substance HBESI

Authorization holder

Curatis AG

4410 Liestal

Authorization information

Swissmedic authorization number
61304
Drug name
Brinavess, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOPA
ATC Code
C01BG11
Authorization status
Z
Dispensing category
B
First authorization
16/03/2011
Authorization expiration date
31/12/9999
IT Number
02.02.0.
Domain
Human medicine
Field of application
Antiarrhythmikum

Package details

Description (FR)
BRINAVESS conc perf 500 mg/25ml flac 25 ml
Description (DE)
BRINAVESS Inf Konz 500 mg/25ml Durchstf 25 ml
Market launch
16/03/2011
Narcotic (BTM)
No